Business Context and Reporting Period
Alector, Inc. is a clinical-stage biopharmaceutical company pioneering "immuno-neurology," a therapeutic approach targeting immune dysfunction as a root cause of neurodegenerative diseases. The company focuses on developing therapies for Frontotemporal Dementia (FTD), Alzheimer's disease, and Parkinson's disease. This Form 10-K covers the fiscal year ended December 31, 2018. As of the filing date, Alector had completed its Initial Public Offering (IPO) in February 2019.
Key Financial Metrics
| Metric (in thousands) | 2018 | 2017 | 2016 |
|---|---|---|---|
| Total Revenue | $27,677 | $3,735 | $416 |
| Net Loss | $(52,248) | $(32,480) | $(15,110) |
| Research & Development Expenses | $73,031 | $29,911 | $13,674 |
| General & Administrative Expenses | $11,934 | $6,503 | $1,874 |
| Cash, Cash Equivalents, & Marketable Securities | $290,408 | $32,451 | $50,838 |
| Accumulated Deficit | $(114,435) | $(62,187) | $(29,707) |
Liquidity: As of December 31, 2018, the company held $290.4 million in cash and marketable securities. In February 2019, the company raised an additional $168.2 million in net proceeds from its IPO. Management believes these funds are sufficient to finance operations for at least the next 12 months from the filing date.
Material Changes vs. Prior Period
- Revenue Surge: Total revenue increased by $23.9 million (641%) year-over-year, driven primarily by collaboration revenue recognized from upfront payments under a strategic agreement with AbbVie. Collaboration revenue rose from $2.9 million in 2017 to $27.5 million in 2018.
- Expense Growth: Operating expenses increased by $48.6 million to $85.0 million. Research and Development (R&D) expenses more than doubled to $73.0 million, reflecting the advancement of four product candidates (AL001, AL002, AL003, AL101) into or preparation for Phase 1 clinical trials.
- Net Loss Expansion: Net loss widened to $52.2 million from $32.5 million in 2017, consistent with the significant increase in R&D spending required for clinical development.
- Balance Sheet Strength: Cash and marketable securities increased by $258 million, largely due to the receipt of a $200 million upfront payment from AbbVie in January 2018 and proceeds from Series E preferred stock issuances.
Guidance, Outlook, and Risks
Management Commentary and Outlook
- Clinical Progress:
- AL001 (FTD-GRN): Completed Phase 1a dosing in healthy subjects in Q1 2019. The study achieved its primary endpoint with no drug-related serious adverse events and demonstrated proof-of-mechanism via statistically significant increases in PGRN levels. Phase 1b in patients is expected in H1 2019, with Phase 2 proof-of-concept data expected in H1 2020.
- AL002 (Alzheimer's): Initiated Phase 1a dosing in healthy subjects in H2 2018.
- AL003 (Alzheimer's): Planned to initiate Phase 1a in H1 2019.
- AL101 (Multiple Neurodegenerative Disorders): Expected to initiate Phase 1 in H2 2019.
- Strategic Partnership: The company has a global strategic alliance with AbbVie for the development of AL002 and AL003. Alector received $205 million in upfront payments and is eligible for up to $985.6 million in additional milestone payments and profit sharing.
- Future Funding: The company expects to incur significant losses for the foreseeable future and will require substantial additional financing to complete development and commercialization.
Risks and Contingencies
- Development Risk: As a clinical-stage company with no approved products, Alector faces high risks regarding the safety and efficacy of its product candidates. Clinical trials may fail, or results may not support regulatory approval.
- Capital Requirements: The company has a history of net losses and an accumulated deficit of $114.4 million. Continued operations depend on securing additional capital, which may result in dilution or restrictive covenants.
- Regulatory Uncertainty: Approval processes are lengthy and unpredictable. The company relies on third-party manufacturers for clinical supply, introducing potential supply chain risks.
- Intellectual Property: Success depends on obtaining and maintaining patent protection, which is subject to legal challenges and changes in patent law.
Key Facts for Investor Verification
- Revenue Recognition: Verify the methodology for recognizing the $205 million AbbVie upfront payment as revenue over time based on incurred costs versus total expected costs.
- Cash Runway: Confirm the current cash burn rate and the sufficiency of the $290.4 million (plus IPO proceeds) to fund operations through the planned Phase 2 trials in 2020.
- Clinical Milestones: Monitor the upcoming Phase 1b data for AL001 in FTD-GRN patients (expected H1 2019) as a critical proof-of-concept checkpoint.
- AbbVie Option Exercise: Track whether AbbVie exercises its option to co-develop AL002 and AL003, which would trigger additional payments and shared development costs.
- Manufacturing Reliance: Assess the stability of relationships with third-party contract manufacturers (Lonza, Celonic, EMD Millipore) given the company has no internal manufacturing capabilities.